Who are Wydase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Triamcinolone plus hyruan, HyQvia, Hylan GF-20 alone, Emervel® Touch, Recombinant antithrombin (rhAT), vitagen plus hyruan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyaluronidase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Wydase — Competitive Intelligence Brief

Wydase (HYALURONIDASE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endoglycosidase. Area: Oncology.

marketed Endoglycosidase hyaluronic acid Oncology Enzyme Live · refreshed every 30 min

Target snapshot

Wydase (HYALURONIDASE) — Baxter. Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Wydase TARGET	HYALURONIDASE	Baxter	marketed	Endoglycosidase	hyaluronic acid	1950-01-01
Triamcinolone plus hyruan	Triamcinolone plus hyruan	Taipei Medical University	marketed	Corticosteroid + viscoelastic agent combination	Glucocorticoid receptor (triamcinolone); hyaluronic acid receptor (CD44, RHAMM) for hyruan
HyQvia	HyQvia	Takeda	marketed	Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin	Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement
Hylan GF-20 alone	Hylan GF-20 alone	University of Sao Paulo General Hospital	marketed	Viscosupplement	Hyaluronic acid receptor (CD44)
Emervel® Touch	Emervel® Touch	Hexsel Dermatology Clinic	marketed	Dermal filler	Hyaluronic acid receptor (CD44)
Recombinant antithrombin (rhAT)	Recombinant antithrombin (rhAT)	Mayo Clinic	marketed	Dispersion agent; enzyme	Hyaluronic acid and connective tissue polysaccharides
vitagen plus hyruan	vitagen plus hyruan	Taipei Medical University	marketed	Viscosupplement / Joint lubricant	Hyaluronic acid receptor (CD44); joint synovial fluid

Recent regulatory actions (last 90 days)

2026-02-13 — Wydase · FDA · approved · US · Baxter

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endoglycosidase class)

Baxter · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Wydase — Competitive Intelligence Brief. https://druglandscape.com/ci/hyaluronidase. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab